BACKGROUND: Thyroid dysfunction is occasionally reported after the administration of nivolumab. We report on the incidence of and risk factors for nivolumab-induced thyroid dysfunction in patients with non-small lung cancer. PATIENTS AND METHODS: A total of 82 patients who received nivolumab between January 2016 and December 2016 at the Kanagawa Cancer Center were included. Prior to nivolumab treatment, 72 patients had normal thyroid function. RESULTS: Among the 72 patients with normal thyroid function prior to nivolumab treatment, the incidence of thyroid dysfunction was 19.5%. There were no significant differences between patients in whom thyroid dysfunction had occurred regarding sex, age, nivolumab dose, or thyroid function prior to nivolumab administration. However, the total number of doses of nivolumab was significantly greater in patients who developed thyroid dysfunction after nivolumab treatment (p=0.03). CONCLUSION: The total number of doses administered may be a risk factor for the development of thyroid dysfunction after nivolumab therapy. Copyright
BACKGROUND:Thyroid dysfunction is occasionally reported after the administration of nivolumab. We report on the incidence of and risk factors for nivolumab-induced thyroid dysfunction in patients with non-small lung cancer. PATIENTS AND METHODS: A total of 82 patients who received nivolumab between January 2016 and December 2016 at the Kanagawa Cancer Center were included. Prior to nivolumab treatment, 72 patients had normal thyroid function. RESULTS: Among the 72 patients with normal thyroid function prior to nivolumab treatment, the incidence of thyroid dysfunction was 19.5%. There were no significant differences between patients in whom thyroid dysfunction had occurred regarding sex, age, nivolumab dose, or thyroid function prior to nivolumab administration. However, the total number of doses of nivolumab was significantly greater in patients who developed thyroid dysfunction after nivolumab treatment (p=0.03). CONCLUSION: The total number of doses administered may be a risk factor for the development of thyroid dysfunction after nivolumab therapy. Copyright
Authors: D L Morganstein; Z Lai; L Spain; S Diem; D Levine; C Mace; M Gore; J Larkin Journal: Clin Endocrinol (Oxf) Date: 2017-01-27 Impact factor: 3.478
Authors: Suzanne L Topalian; Mario Sznol; David F McDermott; Harriet M Kluger; Richard D Carvajal; William H Sharfman; Julie R Brahmer; Donald P Lawrence; Michael B Atkins; John D Powderly; Philip D Leming; Evan J Lipson; Igor Puzanov; David C Smith; Janis M Taube; Jon M Wigginton; Georgia D Kollia; Ashok Gupta; Drew M Pardoll; Jeffrey A Sosman; F Stephen Hodi Journal: J Clin Oncol Date: 2014-03-03 Impact factor: 44.544
Authors: Ricardo Costa; Benedito A Carneiro; Mark Agulnik; Alfred W Rademaker; Sachin G Pai; Victoria M Villaflor; Massimo Cristofanilli; Jeffrey A Sosman; Francis J Giles Journal: Oncotarget Date: 2017-01-31
Authors: Chanjuan Ma; F Stephen Hodi; Anita Giobbie-Hurder; Xiaocheng Wang; Jing Zhou; Amy Zhang; Ying Zhou; Fei Mao; Trevor E Angell; Chelsea P Andrews; Jiani Hu; Romualdo Barroso-Sousa; Ursula B Kaiser; Sara M Tolaney; Le Min Journal: Cancer Immunol Res Date: 2019-05-14 Impact factor: 11.151
Authors: Melissa G Lechner; Mandy I Cheng; Anushi Y Patel; Aline T Hoang; Natalie Yakobian; Michael Astourian; Marissa S Pioso; Eduardo D Rodriguez; Ethan C McCarthy; Willy Hugo; Trevor E Angell; Alexandra Drakaki; Antoni Ribas; Maureen A Su Journal: J Immunol Date: 2022-07-11 Impact factor: 5.426
Authors: Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min Journal: Endocr Rev Date: 2019-02-01 Impact factor: 19.871